Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).

Salek MS, Finlay AY, Lewis JJ, Sumner MI.

Qual Life Res. 2004 Feb;13(1):91-5.

PMID:
15058791
2.

Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.

Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY.

Br J Dermatol. 2001 May;144(5):967-72.

PMID:
11359382
3.

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, Reitamo S, Ohannesson A, Mørk NJ, Clarke P, Pfister P, Paul C.

Br J Dermatol. 1999 Aug;141(2):283-91.

PMID:
10468801
4.

Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.

Ito T, Furukawa F, Iwatsuki K, Matsue H, Shimada S, Takigawa M, Tokura Y.

J Dermatol. 2014 May;41(5):377-81. doi: 10.1111/1346-8138.12455. Epub 2014 Mar 15.

PMID:
24628433
5.

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.

Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE; Sirolimus European Psoriasis Study Group.

Br J Dermatol. 2001 Sep;145(3):438-45.

PMID:
11531834
6.

Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.

Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJ, Boffa MJ, Norris PG, Friedmann PS, Graham-Brown RA, Dowd PM, Marks R, Sumner MJ.

Br J Dermatol. 1997 Apr;136(4):527-30.

PMID:
9155952
7.

Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.

Pedraz J, Daudén E, Delgado-Jiménez Y, García-Río I, García-Díez A.

J Eur Acad Dermatol Venereol. 2006 Jul;20(6):702-6.

PMID:
16836499
8.

Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.

Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB.

Am J Clin Dermatol. 2010;11(4):275-83. doi: 10.2165/11530380-000000000-00000.

PMID:
20513160
9.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

10.

Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.

Gulliver WP, Murphy GF, Hannaford VA, Primmett DR.

Br J Dermatol. 1996 Sep;135 Suppl 48:35-9.

PMID:
8881903
11.

Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.

Ojeda R, Sánchez Regaña M, Massana J, Oliete R, Umbert P.

J Dermatolog Treat. 2005;16(4):238-41.

PMID:
16249146
12.

Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.

Zachariae H, Abrams B, Bleehen SS, Bräutigam M, Burrows D, Ettelt MJ, Fry L, Happle R, Haustein UF, Ganslandt J, Jung EG, Knop J, Kühne KH, Mellein B, Mørk NJ, Rogers S, Schmidt AG, Schopf RE, Sumner M, Taube KM, Weidinger G, Wurdel C, Zahn E.

Dermatology. 1998;196(2):231-6.

PMID:
9568413
13.

Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.

Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A.

J Eur Acad Dermatol Venereol. 2007 Oct;21(9):1203-8.

PMID:
17894706
14.

Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.

Meffert H, Bräutigam M, Färber L, Weidinger G.

Acta Derm Venereol. 1997 Mar;77(2):137-41.

PMID:
9111826
15.

Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.

Peluso AM, Bardazzi F, Tosti A, Varotti C.

Acta Derm Venereol Suppl (Stockh). 1994;186:90-1.

PMID:
8073851
16.

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11.

PMID:
18187944
17.

A global approach to psoriatic patients through PASI score and Skindex-29.

Prignano F, Ruffo G, Ricceri F, Pescitelli L, Lotti T.

G Ital Dermatol Venereol. 2011 Feb;146(1):47-52.

PMID:
21317856
18.

Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.

Shintani Y, Kaneko N, Furuhashi T, Saito C, Morita A.

J Dermatol. 2011 Oct;38(10):966-72. doi: 10.1111/j.1346-8138.2011.01228.x. Epub 2011 May 4.

PMID:
21545506
20.

Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.

Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R.

J Dermatol. 2011 May;38(5):465-72. doi: 10.1111/j.1346-8138.2010.01041.x. Epub 2010 Oct 6.

PMID:
21352289

Supplemental Content

Support Center